3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Early de-escalation of DAPT after PCI: Implications of the latest randomized trials in the COVID era

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Sir, Coronavirus disease 2019 (COVID-19) has changed the way we practice cardiology. All of a sudden, the focus of a cardiologist’s practice has shifted from primary percutaneous coronary intervention (PCI) to thrombolysis, from myocardial infarction to COVID-19 associated myocarditis, from looking for ST-T changes on an electrocardiogram to the measurement of QTc, and from routine heavy OPDs to teleconsultations. COVID-19 has changed us all. Next, we might have to change our practice pattern of dual antiplatelet therapy (DAPT) in post PCI patients. This change seems pivotal in the view of the latest data from the recently published randomized controlled trials (RCTs) on the use of DAPT in post PCI patients 1 , 2 , 3 , 4 , 5 , in conjunction with the heightened risk of thrombocytopenia and bleeding associated with COVID-19 6,7. Studies have shown that thrombocytopenia frequently occurs in patients with COVID-19. 6 Furthermore, the autopsy studies have shown the frequent occurrence of diffuse alveolar hemorrhage in coronavirus induced lung damage. Such observations suggest a high bleeding tendency associated with COVID-19. 7 , 8 DAPT remains the cornerstone therapy in the prevention of ischemic events following PCI. Despite numerous clinical trials, controversy exists regarding the optimal duration of DAPT after PCI with drug-eluting stent (DES). 9 , 10 All major cardiology society guidelines recommend at least six months of DAPT (aspirin and a P2Y12 inhibitor) following PCI for stable coronary artery disease and 12 months of DAPT in the setting of an acute coronary syndrome (ACS). 1 , 2 However, in the last 1-2 years, multiple RCTs viz. TICO, TWILIGHT, SMART-CHOICE, and STOPDAPT-2, have demonstrated that early de-escalation of DAPT (1-3 months) to P2Y12 inhibitor monotherapy instead of aspirin is associated with a lower risk of total bleeding events compared with 12 months of DAPT. 1 , 2 , 3 , 4 This benefit is achieved without increasing the risk of ischemic outcomes or mortality (See Table 1 ). Reduced bleeding with no increase in ischemic end-points favors 1-3 months DAPT followed by P2Y12 inhibitor monotherapy in patients with PCI and DES. This approach appears much more appealing in the current context of the COVID-19 pandemic, which is frequently associated with thrombocytopenia and bleeding complications. Table 1 Recent trials evaluating the short duration DAPT (dual antiplatelet therapy) in post PCI (Percutaneous intervention) patients. Table 1 Trial Name (Year of publication) Methods Results Interpretation TICO(March 2020) 1 1. Randomized, open label trial involving 3056 patients. 2. ACS treated with the ultrathin bioresorbable polymer sirolimus-eluting stent (Orsiro). 3. Ticagrelor monotherapy after 3 months of DAPT (n=1527) was compared with 12 months of Ticagrelor based DAPT (n=1529) after PCI for ACS 1. Primary outcome (composite of death, MI, stent thrombosis, stroke, TVR, TIMI major bleeding) at 12 months occurred in 3.9% in monotherapy group versus 5.9% in standard DAPT group (p=0.01). 2. Secondary outcome of major bleeding occurred in 1.7% of monotherapy group compared with 3% of standard therapy (p=0.02). The TICO trial showed that ticagrelor monotherapy after 3 months of DAPT was superior at preventing ischemia and bleeding after PCI for ACS. TWILIGHT(Nov 2019) 2 1. Randomized. double blind, placebo controlled trial involving 7119 patients 3 months post PCI (for stable angina in 29%). 2. Short duration DAPT (3 months) followed by ticagrelor monotherapy was compared with longer duration DAPT (12 months) among patients undergoing PCI with a DES and with ≥1 high risk feature of ischemia or bleeding. 1. The primary end point of BARC type 2, 3, or 5 bleeding, between randomization at 3 months post PCI and 12 months, occurred in 4.0% among patients randomly assigned to receive ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor plus aspirin (p<0.001). 2. The incidence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in both groups (p <0.001 for noninferiority) The TWILIGHT trial showed that Ticagrelor monotherapy after 3 months of DAPT was superior at preventing bleeding compared with longer-duration DAPT (additional 12 months) among patients undergoing PCI with a DES and at high ischemic or bleeding risk.Ischemic rates met criteria for noninferiority.These results were maintained among the subgroup of patients presenting with Non ST-elevation ACS, Diabetes mellitus, and those undergoing complex PCI. STOPDAPT-2(June 2019) 3 1. Randomized, open label trial, involving 3045 patients undergoing PCI (for stable angina in 62%). 2. Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522). 3. In the initial 1 month 62% of patients received clopidogrel in addition to aspirin, while 38% received Prasugrel in addition to aspirin as part of DAPT. After 1 month, those who received prasugrel initially were switched to clopidogrel. 1. The primary end point defined as the composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding at 12 months occurred in 2.36% of patients with 1-month DAPT compared to 3.70% of patients with 12-month DAPT, meeting the criteria for noninferiority (p < .001) and for superiority (p = .04). 2. Composite of death, MI, stent thrombosis, or stroke at 1 year occurred in 2.0% of patients in the 1-month DAPT group compared with 2.5% of patients in the 12-months DAPT group (p for noninferiority = 0.005) 3. TIMI major/minor bleeding at 1 year occurred in 0.4% of patients in the 1-month DAPT group compared with 1.5% of patients in the 12-months DAPT group (p for superiority = 0.004) One-month DAPT was noninferior to 12-month DAPT at preventing major adverse ischemic events and superior to 12-months DAPT at preventing TIMI major/minor bleeding. SMART-CHOICE(June 2019) 4 1. Randomized, open label trial, involving 3045 patients undergoing PCI (for stable angina in 42%). 2. Short-duration DAPT (3 months) followed by P2Y12 inhibitor monotherapy (n = 1,495) was compared with longer duration DAPT for 12 months (n = 1,498) among patients undergoing PCI. 3. Clopidogrel was used in 77% of patients, while prasugrel/ticagrelor were used in remaining 23% of patients. 1. The primary outcome, MACCE (all-cause death, MI, or stroke) at 12 months, for 3 months vs. 12 months of DAPT, was 2.9% vs. 2.5%, p for noninferiority = 0.007; p for superiority = 0.46. 2. Secondary outcomes of stent thrombosis occurred in 0.2% vs. 0.1% (p = 0.65) in the 3 months vs. 12 months DAPT groups respectively, while the BARC 2-5 grade bleeding was 2.0% vs. 3.4% (p = 0.02) respectively. Short-duration DAPT (3 months) followed by P2Y12 inhibitor monotherapy was noninferior to longer-duration DAPT (12 months) among unselected patients undergoing PCI with a DES. GLOBAL LEADERS(September 2018) 5 1. Randomized, open label trial. 2. Patients undergoing PCI with a biolimus A9-eluting stent for Stable coronary artery disease or ACS were randomly assigned (1:1) to 75–100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy (n= 7980), or standard dual antiplatelet therapy with 75–100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months (n=7988). 1. The primary outcome, all-cause mortality or nonfatal myocardial infarction, occurred in 3.8% of the ticagrelor monotherapy group compared with 4.4% of the control group (p = 0.073). The findings were the same in multiple tested subgroups. 2. Secondary outcomes of all-cause mortality occurred in 2.8% of the ticagrelor monotherapy group vs. 3.2% of the control group (p = 0.18). Myocardial infarction 1.0% vs. 1.3%, p = 0.14) and grade 3 or 5 bleeding (2.0% vs. 2.1%, p = 0.77) were also similar between the two groups. Among patients who underwent PCI with a biolimus-eluting stent, 1 month of DAPT followed by ticagrelor monotherapy for 23 months was noninferior, but not superior to 12 months of DAPT followed by aspirin monotherapy for 12 months.The GLASSY substudy revealed that 1 month of DAPT was noninferior to 12 months of DAPT at preventing death, myocardial infarction, stroke, or urgent target vessel revascularization. One month of DAPT also failed to reduce major bleeding events compared with 12 months of DAPT. Abbreviations: ACS=Acute Coronary Syndrome; MI=Myocardial Infarction; TVR=Target Vessel Revascularization; TIMI=Thrombolysis In Myocardial Infarction; DES=Drug Eluting Stent; BARC=Bleeding Academic Research Consortium; MACCE= Major Adverse Cardiac And Cerebrovascular Events; GLASSY= GLOBAL LEADERS Adjudication SubStudY. Regarding the choice of agent for P2Y12 inhibitor monotherapy, ticagrelor appears to have the edge since most of these recent DAPT trials have used ticagrelor as the P2Y12 inhibitor monotherapy. 1 , 2 , 5 Additionally, ticagrelor possesses the most potent anti-inflammatory properties out of all P2Y12 inhibitors 8 , 9 , which might offer additional advantage against the inflammation-mediated organ damage in the setting of COVID-19. Furthermore, the subgroup analysis of the PLATO trial revealed that, compared to clopidogrel, ticagrelor was associated with a lower incidence of subsequent pulmonary events, sepsis, and the associated mortality. 10 Ticagrelor further showed beneficial effects in the setting of pneumonia in the XANTHIPPE trial, where its use led to reduced incidence of lung injury and sepsis. 11 Ticagrelor might also offer another advantage by protecting against the superadded bacterial infections in COVID-19 patients since a recent experimental study demonstrated good antibacterial activity of ticagrelor against antibiotic-resistant gram-positive bacteria with the standard antiplatelet dosages. 12 However, there exist a few concerns too. Some of the investigational therapies for COVID-19 like lopinavir, and ritonavir through their inhibitory effects on the CYP3A4 metabolism, have the potential to increase the blood levels of ticagrelor and its associated bleeding risk. 13 Inhibition of CYP3A4 may also result in decreased conversion of prodrug clopidogrel into its active form, and thereby may decrease its antiplatelet efficacy. 14 Prasugrel is not prone to these interactions and is, therefore, a reasonable choice, in the absence of contraindications, for use with lopinavir and ritonavir. However, the use of prasugrel as the agent for P2Y12 inhibitor monotherapy 1-3 months post PCI is less well studied compared to ticagrelor and clopidogrel. 1 , 2 , 3 , 4 , 5 Data from the national interventional council suggests that approximately 4 lac PCIs are performed in India every year. 15 Since the patients with cardiovascular diseases are more prone to get infected with COVID-19 16 and keeping in mind the upsurge of COVID-19 cases in India in the past two weeks despite the gross under-testing, it is highly likely that many post PCI patients might get affected by this unprecedented pandemic and might develop an elevated bleeding risk. In such exceptional circumstances, it would be apt for us not to wait for the guidelines to change; instead, imbibe on the current evidence-based data and start early de-escalation of DAPT (1-3 months) to P2Y12 monotherapy, preferably with ticagrelor, in our post PCI patients. Funding This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. Author’s Contribution Both the authors made substantial contributions to the conception/design of the work, acquisition, analysis, or interpretation of data, drafting the work or revising it critically for important intellectual content. Both the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work. Declaration of Competing Interest None.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

          Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

            The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and pre-existing cardiovascular disease have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become hosts or vectors of virus transmission. We hereby review the peer-reviewed and pre-print reports pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ticagrelor with or without Aspirin in High-Risk Patients after PCI

              Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).
                Bookmark

                Author and article information

                Contributors
                Role: Assistant Professor
                Role: Consultant Cardiologist
                Journal
                Indian Heart J
                Indian Heart J
                Indian Heart Journal
                Cardiological Society of India. Published by Elsevier B.V.
                0019-4832
                2213-3763
                23 May 2020
                23 May 2020
                Affiliations
                [1 ]Department of Cardiology, Indira Gandhi Medical College, Shimla, India-171001
                [2 ]Holy Heart Advanced Cardiac Care and Research Centre, Rohtak, Haryana, India-124001
                Author notes
                []Corresponding Author: Dr Kunal Mahajan, Assistant Professor, Department of Cardiology, Indira Gandhi Medical College, Shimla=171001, HP, India. Tel.: +91 8628864820 kunalmahajan442@ 123456gmail.com
                Article
                S0019-4832(20)30099-7
                10.1016/j.ihj.2020.05.009
                7244419
                d49a9ef4-cd4a-4200-96a1-481fc20d7586
                © 2020 Cardiological Society of India. Published by Elsevier B.V.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 10 May 2020
                : 14 May 2020
                : 15 May 2020
                Categories
                Article

                dual antiplatelet therapy,descalation,coronavirus,covid-19

                Comments

                Comment on this article